Long noncoding RNA LRRC75A-AS1 inhibits cell proliferation and migration in colorectal carcinoma

Abstract

With the continuous improvement of technology in the molecular field, more and more evidence indicated that long noncoding RNAs (lncRNAs) are widely expressed in a broad spectrum of human tumors, playing an important role in the development and progression of tumors. Most studies reported that lncRNAs might serve as reliable biomarkers and effective clinical therapeutic target. Leucine-rich repeat containing 75 A-antisense RNA1 (LRRC75A-AS1) was reported to be relevant to many types of cancers and indicated to do influence on colorectal carcinoma (CRC). This research firstly examined the role of LRRC75A-AS1 in CRC and analyzed its association with the biological behaviors of CRC cells. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) brought to light that LRRC75A-AS1 was remarkably expressed at low levels in CRC tissues. We also found that LRRC75A-AS1 was localized in the cytoplasm. In addition, LRRC75A-AS1 knockdown also notably promoted CRC cell proliferation, metastasis, invasion, and colony formation. To summarize, these experimental results showed that LRRC75A-AS1 might serve as an anti-oncogene for CRC tumorigenesis and advancement, and it may become a novel molecular marker for clinical diagnosis. Impact statement It is reported that colorectal cancer has seriously threatened human health. The incidence of colorectal cancer in China is increasing year by year. At present, the treatment of cancer is gradually developing towards individualized treatment whose core is targeted therapy, and molecular pathology is the basis of targeted therapy. Previous studies have shown that in addition to protein-coding genes that regulate tumor invasion and metastasis, there are also some non-coding genes involved in tumor encroachment and spread. Our study found that long noncoding RNA LRRC75A-AS1 is closely related to CRC and is related to its proliferation and migration. And it may become a novel molecular marker for clinical diagnosis and treatment.